Thomas Colletti, DHSc, PA-C, DFAAPA
The novel coronavirus, SARS-CoV-2, is responsible for the range of clinical diseases now known as COVID-19. While most cases of COVID-19 are either asymptomatic or consist of mild to moderate disease, a subset of the population develops severe or critical illness. Based on the clinical scenario, there are a variety of pharmacologic and nonpharmacologic therapeutic options. This article reviews recommendations for implementing these therapeutic options in severe or critically ill patients with COVID-19.
Padilla S. Breakthroughs in COVID: a Review of Severe and Critical Illness due to SARS-CoV-2. Lynchburg Journal of Medical Science. 2022; 4(3).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.